Overview

* CareDx ( CDNA ) Q2 adjusted rev grows 14% yr/yr

* Co narrows full-year 2025 revenue guidance to $367 mln to $373 mln

Outlook

* CareDx ( CDNA ) narrows full-year 2025 revenue guidance to $367 mln to $373 mln

* Company expects full-year 2025 adjusted EBITDA of $29 mln to $33 mln

Result Drivers

* ALLOSURE KIDNEY TESTING - Volumes grew nearly 20% yr/yr, driving testing services growth

* CASH COLLECTIONS - Improved cash collections contributed to adjusted EBITDA gain

* FINANCIAL DISCIPLINE - Financial discipline helped achieve adjusted EBITDA improvement

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $86.70

Revenue mln

Q2 Miss $0.1 $0.12 (6

Adjusted Analysts

EPS )

Q2 EPS -$0.16

Q2 Miss $5.60 $6.56

Adjusted mln mln (6

Net Analysts

Income )

Q2 Net -$8.60

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for CareDx Inc ( CDNA ) is $26.00, about 50.6% above its August 5 closing price of $12.85

* The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)